Glenmede Trust CO Na Beam Therapeutics Inc. Transaction History

Glenmede Trust CO Na

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 16, 2022	BUY	$39.79 - $70.31 $181,124 - $320,051	4,552 New	4,552 $216,000
Q2 2022 Aug 15, 2022	SELL	$29.86 - $62.36 $222,068 - $463,771	-7,437 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$53.73 - $82.16 $2,686 - $4,108	50 Added 0.68%	7,437 $425,000
Q4 2021 Feb 15, 2022	BUY	$68.02 - $99.06 $6,802 - $9,906	100 Added 1.37%	7,387 $588,000
Q3 2021 Nov 15, 2021	SELL	$84.37 - $133.6 $4,724 - $7,481	-56 Reduced 0.76%	7,287 $633,000
Q2 2021 Aug 16, 2021	BUY	$64.12 - $128.71 $186,140 - $373,645	2,903 Added 65.38%	7,343 $945,000
Q1 2021 May 18, 2021	BUY	$71.28 - $120.75 $102,643 - $173,880	1,440 Added 48.0%	4,440 $355,000
Q3 2020 Nov 16, 2020	BUY	$19.0 - $30.57 $57,000 - $91,710	3,000 New	3,000 $73,000

236

75.2M

438K

232K

Ticker BEAM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,354,600
Market Cap $1.78B
Description
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...

Get notified when there are updates to the investment portfolio of Glenmede Trust CO Na, based on Form 13F filings with the SEC.

Stay updated on Glenmede Trust CO Na with notifications on news.